Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04860518 · ClinicalTrials.gov registry record · Phase 2
Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19
A Phase 2 study, sponsored by Faron Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04860518 is a Phase 2 study that was terminated before completion, run by Faron Pharmaceuticals. The registered enrollment target is 7 participants.
The verdict
NCT04860518, a Phase 2 study, was terminated before completion, sponsored by Faron Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This double-blinded, randomized study is being conducted to see if the investigational new drug called FP-1201-lyo - intravenous Interferon beta-1a, hereafter IV IFN beta-1a, can help patients recover more quickly from COVID-19 and prevent worsening of the condition. To understand if IV IFN beta-1a can help treat patients with COVID-19, this study drug will be compared to dexamethasone. Study subjects will be treated daily with IV IFN beta-1a 10 μg or IV dexamethasone for 6 consecutive days while hospitalized and will undergo daily assessments while in hospital for a maximum of 28 days. Study specific assessments will be collected at pre-dose Day 1 through Day 28 (PD and PIM assessments), in addition, clinical routine assessments will be utilized for safety and efficacy assessments.
Interventions
- DRUG Dexamethasone
- DRUG IFN beta-1a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2022-04-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04860518
The ClinicalTrials.gov registry entry for NCT04860518 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Faron Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone is the first listed.
NCT04860518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04860518 about?
NCT04860518 is a clinical study titled "Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19". This double-blinded, randomized study is being conducted to see if the investigational new drug called FP-1201-lyo - intravenous Interferon beta-1a, hereafter IV IFN beta-1a, can help patients recover more quickly from COVID-19 and prevent worsening of the condition. To understand if IV IFN beta-1a ...
What is the current status of trial NCT04860518?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2021-08-23. Estimated completion is 2022-04-04.
What interventions are being tested in trial NCT04860518?
The interventions under investigation include: Dexamethasone (DRUG), IFN beta-1a (DRUG).
Who is sponsoring clinical trial NCT04860518?
This trial is sponsored by Faron Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.